Cohance Lifesciences reported a weak Q3 FY26 with consolidated revenue declining 19.5% YoY to ₹545 crore, impacted by destocking in two large commercial products (~₹260 crore im...
Financial stats pending filing verification
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Two large commercial products faced earlier-than-expected volume recalibration due to patent expiry and inventory normalization; similar risks exist for other mature products.
high · management_commentaryThe Nacharam formulation site received a warning letter; US shipments remain suspended, and remediation may take time, impacting ~₹55 crore in deferred shipments.
high · management_commentarySlower decision-making and contract renewals due to biotech funding constraints have muted subsidiary performance and ADC near-term demand.
medium · management_commentaryManagement acknowledged that the pace of commercial ramp-up has been slower than anticipated due to customer launch sequencing and cautious initial scale.
medium · analyst_question